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1. Introduction 
Chemotherapeutic drugs are fundamental in cancer management and are responsible for 
most cases of adjuvant treatment in patients after surgical procedures. However, the median 
overall survival does not increase in patients treated by concurrent chemo-radiotherapy. 
Consequently, further studies that could enhance the therapeutic effect should be 
encouraged [1]. 
Although the biological functions of microRNAs (miRNA) are not completely revealed, 
there is growing evidence that miRNA pathways are a new mechanism of gene regulation in 
both normal and diseased conditions [2]. Recent evidence has shown that miRNA mutations 
or aberrant expression patterns correlate with various diseases, such as cancer, viral 
infections, cardiovascular and indicates that miRNAs can function as tumor suppressors 
and oncogenes and oretically become a target to enhance the chemotherapeutic effect in 
cancer therapy. 
However, although much work has been accomplished, the development of an efficient 
delivery system still remain a major challenge for the wide application of miRNA. In the 
following sections -- after a brief introduction of the miRNA strategies -- the potential and 
contributions of dendrimers in the development of effective non-viral delivery systems for 
combined the microRNA therapy with drug delivery will be discussed. 
2. MicroRNA strategy 
MicroRNAs (miRNAs) are a class of naturally occurring small non-coding RNAs, 
approximately 22 nucleotides in length, that target protein-coding mRNAs at the post-
transcriptional level [4]. Generally, mature miRNAs are integrated into a protein–RNA 
complex called a microRNA RNPs (similar to the RISCs (RNA-induced silencing complexes) 
for siRNA). miRNAs bind through partial sequence homology to the 3_-untranslated 
regions (3’-UTRs) of target genes. Because of this unique feature, a single miRNA has 
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multiple targets. It is thought that more than 30% of human genes are posttranscriptionally 
regulated by miRNAs [5]. miRNAs have diverse functions in biological processes, including 
the regulation of cellular proliferation, differentiation, and cell death. As dysregulation of 
these biological processes frequently occur in human cancer, miRNAs may, therefore, play a 
critical role in the process of tumorigenesis. 
This regulatory mechanism was first shown in the developmental processes in worms, flies, 
and plants [6]. Subsequently, miRNAs have been shown to have important roles in many 
physiological processes of mammalian systems by influencing cell apoptosis, development, 
and metabolism through regulation of critical signaling molecules including cytokines, 
growth factors, transcription factors, and pro-apoptotic and anti-apoptotic proteins. 
Increasing number of miRNAs have been identified in the human genome and they are 
collectively called the miRNome [7]. Accumulating evidence shows the potential 
involvement of altered regulation of miRNAs in initiation and progression in a wide range 
of human cancers. Altered expression profiles of miRNAs are associated with genetic and 
epigenetic alterations including deletion, amplification, point mutation, and aberrant DNA 
methylation. 
2.1 miR-21 general aspects 
MiR-21 has been identified as the best hit in a number of miRNA profiling studies 
designed for the detection of miRNAs dysregulated in human cancer [8]. MiR-21 could 
suppress several tumor suppressor proteins translation, including PTEN, PDCD4, TMP1 
and p53, to mediated cancer cell malignant phenotype alternation [9-10]. MiR-21 was 
emerging as key regulators of multiple pathways involved in tumorgenesis and may 
become the next targeted therapies in human cancers [11]. Previously we identified miR-
21’s aberrant expression in glioblastoma(GBM), and we focused on in what way miR-21 
regulated GBM development and progression. Thus, in the current chapter, we manage to 
elucidate the view point that miR-21 was an effective molecule with great potential of 
human cancer gene therapy; of course, we will take miR-21’s biological role to GBM as an 
example. 
Recent reports suggested that miR-21 functions as an oncogene in human cancers. Ciafre` et 
alprofiled the expression of 245 miRNAs in 10 glioblastoma (GBM) cell lines and nine 
freshly resected GBM samples and observed that miR-21 was overexpressed in human brain 
tumors [12]. It was shown that when miR-21 was suppressed, cell growth inhibition and 
caspase-dependent apoptosis were observed in A172, U87, LN229, and LN308 cells. It has 
been shown that miR-21 modulates breast cancer cell anchorage-independent growth 
through suppressing TMP1 expression. In human colorectal, breast cancer, and renal cell 
carcinoma, miR-21 contributes to invasion and metastasis cell by inhibiting Pdcd4 mRNA at 
the post-transcription level. A recent study showed that miR-21 targets PTEN gene through 
a binding site on the 3’-UTR in hepatocellular carcinoma [13]. PTEN has been shown to be a 
critical tumor suppressor gene that is commonly inactivated in GBM by deletion, mutation, 
or attenuated expression. Thus, increased expression of miR-21 may contribute to the 
attenuated expression of PTEN in GBM. 
2.2 miR-21 was up regulated in GBM cell lines and tissue samples 
Microarray assay was used to screen the miRNA expression status in GBM cell lines. Data 
showed miR-21 exhibited a 7.0-fold increase relative to normal brain tissue [14]. In addition, 
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in-situ hybridization (ISH) of surgery resected glioma samples proved that miR-21 
displayed varying degrees of intensity in glioma with different grades and the positive rate 
increased with the ascending order of the glioma WHO grade. In hence, it was important to 
note that miR-21 ISH was conducted at both the tissue level and the cellular level to indicate 
that miR-21 disregulation could be a marker to predict the outcome of glioma patients. 
To identify miR-21 that was abnormal upregulated in high-grade gliomas, we used ISH to 
test miR-21 insitu expression in human non-neoplastic brain tissues, I~II grade gliomas, 
grade III gliomas (anaplastic gliomas, AAs) and GBMs. 
Our group showed that miR-21 was over expressed in 57 of 60 glioma samples and miR-21 
was detected in the cytoplasm of the neoplastic cells of all the positive cases. MiR-21 
displayed varying degrees of intensity in glioma with different grades and the positive rate 
increased with the ascending order of the WHO grade. There were 27 of 30 (90%) in WHO I 
and II gliomas, 15 of 15 (100%) in AAs and GBMs, whereas miR-21 was rarely detected in 
control brain tissues. The first indication of miR-21’s aberrant expression came from the 
miRNA profiling of human glioblastoma. Compared to normal brain tissue, miR-21 relative 
expression was seven to eleven folds in low-grade astrocytomas, AAs and GBMs. Besides 
providing the consistent data to the previous study, it is important to note that miR-21 ISH 
was conducted at both the tissue level and the cellular level to indicate that miR-21 
disregulation could be a marker to predict the outcome of glioma patients. 
2.3 miR-21 regulated GBM cell growth in vitro and in vivo 
To evaluate the significance of miR-21 overexpression in glioma cells, we used a loss-of-
function antisense approach. An As-miR-21 oligonucleotide (ODN) was used to knock down 
miR-21 expression in U251 and LN229 cells. RT-realtime PCR results determined that the 
relative expression level of miR-21 in As-miR-21 ODN-treated U251 cell was 6.25% (P<0.01) 
and 12.5% for LN229 cells (P<0.01) compared with their control cells, respectively. In addition, 
LNA-based in situ hybridization showed that transfection of a scrambled ODN had no effect 
on miR-21 expression. In contrast, the cy3 red fluorescence signal in As-miR-21-transfected 
U251 cells was lower (Figure 1B). These data suggested that As-miR-21 can specifically inhibit 
the endogenous miR-21 expression in U251 and LN229 cells. 
The GBM cell growth inihibitory effect (MTT assay) of decreased miR-21 reached maximum 
three days post transfection. G1 phase blockage was observed to indicate cell cycle 
distribution changed significantly after miR-21 inhibitory. Additionally, the Annexin V 
positive early phase apoptotic cells were significantly increased in cells transfected with AS-
miR-21 as compared to that in parental cells and cells treated with scrambled ODN.  
The in vitro experiments suggest that miR-21 is a potential target for therapy in GBM. To 
further confirm this, we performed a proof-of-principle experiment using a U251 glioma 
xenograft model and a lipofectamine-mediated gene therapy approach. The xenograft tumors 
volume suppression indicated that miR-21 contributed a lot to U251 GBM cell proliferation in 
vivo. Pathological examination found micro-vessel density indicated that was and evaluated 
miR-21 expression by in situ hybridization and cellular apoptosis by TUNEL assay. 
Despite the apparently predominance of microRNA in cancer therapy, several problems 
have to be overcome for successful clinical application. They show a poor stability towards 
nuclease activity, low intracellular penetration and low bioavailability. Although chemical 
modifications were brought to the basic microRNA, their sensitivity to degradation and 
poor intracellular penetration is still hampering their widespread clinical applications. In 
fact, the major bottleneck in the development of miRNA strategy is the delivery of these 
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macromolecules to the target cells, tissues or organs. Therefore the development of more 
efficient delivery systems is regarded as one of the most promising strategies to solve these 
pharmaceutical hurdles. Specifically, delivery vectors must be designed to effectively 
complex with nucleic acid molecules and aid in overcoming intracellular barriers such as 
endosomal escape and cytoplasmic vector dissociation. For that reason, improvements on 
effective delivery have progressed rapidly. Among the different approaches under study, 
dendrimers are attracting a great interest for their well defined structure and great 
versatility in their chemistry that offer a unique platform for the rational design of efficient 
antisense delivery systems. 
 
 
Fig. 1. The effect of miR-21 knockdown on U251 and LN229 GBM cell proliferation. (A) miR-21 
was overexpressed in six glioma cells. (B) In situ examination of miR-21 expression in U251 
cells. Arrows highlight miR-21 in situ expression in U251 cells. Bar¼20 mm. (C、D) MTT cell 
proliferation assay. miR-21 knockdown in U251 and LN229 GBM inhibits cell proliferation in 
vitro and in vivo. (E) Cell-cycle profiles after PI staining. miR-21 knockdown induced G1 arrest 
in both U251 and LN229 GBM cells. (F). As-miR-21 and scramble ODN-transfected U251 and 
LN229 GBM cells were analyzed using FCM to determine cell-cycle status.  
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3. Polyamidoamine (PAMAM) dendrimers 
Recently, a great deal of attention has been given to polyamidoamine (PAMAM) 
dendrimers; these are one of the most appropriate candidates for suitable carrier systems. 
PAMAM dendrimers represent an exciting new class of macromolecular architecture called 
dense star polymers. Unlike classical polymers, dendrimers have a high degree of molecular 
uniformity, a narrow molecular weight distribution, specific size and shape character [15]. 
The terminal amine groups of PAMAM dendrimers can be modified with different 
functionalities and can be linked with various biomolecules. These unique structural 
features of PAMAM dendrimers make them ideal nanoplatforms to conjugate biologically 
important substances. 
3.1 PAMAM dendrimer in gene transfection 
Gene therapy is a promising approach for the treatment of cancer because it enables the 
production of bioactive agents or the cessation of abnormal functions in the tumor cell. 
However, the success of gene therapy requires efficient and safe transfer systems because of 
the degradation of the delivered gene in the systemic circulation.  
A variety of molecules including polymers, lipids, and peptides have been studied for their 
effectiveness as delivery vectors for DNA and RNA molecules. Successful delivery vectors 
must exhibit a combination of functional attributes. Polymeric carrier molecules should be 
cationic to complex with nucleic acids, possess a high buffering capacity, exhibit low 
cytotoxicity, and also contain chemically reactive groups that can be modified for the 
addition of targeting moieties or other groups. 
As a non-viral gene delivery carrier, highly branched, dendritic polymers including 
poly(amidoamine) (PAMAM) have recently attracted interest as nucleic acid delivery 
vectors. Previous work has demonstrated that dendrimers can bind to DNA and RNA 
molecules and mediate modest cellular delivery of these nucleic acids. (PAMAM) 
dendrimers have attracted great interest due to their high efficacy in vitro gene delivery 
because of their branched structure. These dendritic polymers bear primary amine groups 
on their branched surface, which can bind DNA, compact it into polyplexes, and promote 
the cellular uptake of genes. Therefore, PAMAM dendrimers show high levels of 
transfection in a wide variety of cultured cells, especially in fractured form of G5 
(commercially named SuperFect). Enhanced transfection efficiency has been reported by 
surface modification of PAMAM with L-arginine. Moreover, the primary amines located on 
the surface of PAMAM make it possible to conjugate suitable ligands, such as Transferrin, 
for efficient brain-targeting gene delivery. 
Studies that focus on the cell entry mechanisms for several nonviral vectors, including 
PAMAM dendrimers [16]. The cationic surface charge imparted to the complex through 
high dendrimer–DNA charge ratios is required for subsequent interaction with the anionic 
glycoproteins and phospholipids that reside on the cell membrane surface. This interaction 
initiates the interior movement of the dendrimer–DNA complex into the cell cytosol, either 
by passive transport caused by membrane perturbations or by endocytosis. Complexes 
formed without an excess cationic surface charge do not mediate high gene transfection 
efficiency, which furnishes support for the importance of the initial electrostatic interaction 
between the complex and cell membrane. Studies following the incorporation of 
radiolabeled DNA and/or dendrimer components into cells established that the uptake in 
most cells was primarily via an active endocytosis mechanism. Cells preincubated with 
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inhibitors of endocytosis (i.e. cytochalasin B and deoxyglucose) or cellular metabolism (i.e. 
sodium azide) reduced the uptake that corresponded to lower transgene expression, 
regardless of cell type. 
These dendrimers as nanocarriers possess the following advantages: (1) neutral surface of 
the dendrimer for low cytotoxicity; (2) existence of cationic charges inside the dendrimer 
(not on the outer surface) resulting in highly organized compact nanoparticles, which can 
potentially protect nucleic acids from degradation. Noteworthly, surface modified 
QPAMAM-NHAc dendrimer demonstrated enhanced cellular uptake of siRNA when 
compared with the internally cationic QPAMAM-OH dendrimer (degree of 
quaternization 97%).  
George’s study shows PEG-G5 and PEG-G6 dendrimers, with PEG conjugation molar ratio 
at 8% (PEG to surface amine per PAMAM), can facilitate dramatic intramuscular gene 
delivery in neonatal mice [17]. Park’s group concluded that di-arginine conjugation to 
PAMAM dendrimers can improve polyplex stability, ntra-nuclear localization, and 
transfection efficiency but also induce charge density- and generation-dependent 
cytotoxicity. Therefore, a novel strategy for highly densed arginine conjugation maintaining 
low cytotoxicity will be needed for the development of efficient gene delivery carriers [18]. 
3.2 PAMAM dendrimer as drug delivery system 
Polymeric drug delivery can improve bioavailability and efficacy of therapeutics with 
intrinsically poor water solubility and high toxicity. Dendrimers, a class of highly branched 
polymers, are effective drug delivery vehicles due to their monodispersity and nanoscopic 
size. With each increase in dendrimer generation, the diameter increases linearly while the 
number of surface groups increases exponentially. These high density surface groups can be 
conjugated to drug molecules, targeting moieties and imaging agents, rendering dendrimers 
a versatile drug delivery platform. In addition, surface groups on dendrimers can be 
modified to modulate cytotoxicity and permeation across biological barriers. 
During their synthesis, PAMAM dendrimers can be produced that are either anionic or 
cationic in nature, with “full generations” (ie. G1, G2) having amine terminal groups and 
“half generations” (ie, G0.5, G1.5) possessing carboxylic acid terminal groups. The size and 
charge of PAMAM dendrimers impact their cytotoxicity and transepithelial transport, with 
cationic dendrimers showing higher toxicity in vitro. Due to their intrinsically low 
cytotoxicity and appreciable transepithelial permeation characteristics across Caco-2 
monolayers and everted rat intestinal sac models, anionic dendrimers show distinct 
advantages as vehicles for oral drug delivery, with higher generation dendrimers showing 
the greatest potential because of their large number of modifiable surface groups.  
PAMAM has well-defined internal cavities and an open architecture, guest molecules can 
become directly encapsulated into the macromolecule interior through hydrophobic 
interactions. Drug-polymer conjugates are potential candidates for the selective delivery of 
anticancer agents to tumor tissue. The main advantages of conjugating drugs to polymeric 
carriers include an increase in water solubility of low soluble or insoluble drugs, and 
therefore, enhancement of drug bioavailability, protection of drug from deactivation and 
preservation of its activity during circulation, a reduction in antigenic activity of the drug 
leading to a less pronounced immunological body response, and the ability to provide 
passive or active targeting of the drug specifically to the site of its action. 
Surface-modified dendrimers were predicted to enhance pilocarpine bioavailability [19]. 
The anticancer drugs adriamycin and methotrexate were encapsulated into PAMAM 
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dendrimers (i.e. G=3 and 4) which had been modified with PEG monomethyl ether chains 
(i.e. 550 and 2000 Da respectively) attached to their surfaces. A similar construct involving 
PEG chains and PAMAM dendrimers was used to deliver the anticancer drug 5-
fluorouracil. Encapsulation of 5-fluorouracil into G=4 increase in the cytotoxicity and 
permeation of dendrimers. 
Dendrimers have ideal properties which are useful in targeted drug-delivery system. One of 
the most effective cell-specific targeting agents delivered by dendrimers is folic acid 
PAMAM dendrimers modified with carboxymethyl PEG5000 surface chains revealed 
reasonable drug loading, a reduced release rate and reduced haemolytic toxicity compared 
with the non-PEGylated dendrimer. A third-generation dendritic unimolecular micelle with 
indomethacin entrapped as model drug gives slow and sustained in vitro release, as 
compared to cellulose membrane control [20]. Controlled release of the Flurbiprofen could 
be achieved by formation of complex with amine terminated generation 4 (G4) PAMAM 
Dendrimers [21]. The results found that PEG-dendrimers conjugated with encapsulated 
drug and sustained release of methotrexate as compare to unencapsulated drug. 
4. Multifunctional dendrimer nanodevices: In vitro and in vivo testing 
4.1 Target gene therapy to rat C6 glioma cells rhrough folate receptor-PAMAM  
Despite the progress in the PAMAM mediated gene delivery, few studies have investigated 
the suitability of PAMAM dendrimers for ASODN delivery in vivo, especially for brain 
gliomas. The purpose of the present study is to evaluate whether in vivo gene delivery by 
folate-PAMAM (G5) conjugates can inhibit the development of gliomas. We selected the 
EGFR gene as an antisense target and the rat C6 intracranial glioma model for the in vivo 
study. Synthetic foliated (FA-)PAMAM was complexed with EGFR ASODN, and then the 
gene transfection efficacy, dynamic uptake, and biological effects of the FA-PAMAM 
delivery system on C6 rat glioma cells were investigated both in vitro and in vivo. Our 
results showed that the FA-PAMAM dendrimer conjugates transported EGFR-ASODNs into 
glioma cells in vitro, and yielded a favorable therapeutic effect in vivo on administration by 
local perfusion. Therefore, FA-PAMAM may represent a potential delivery system for short 
oligonucleotides in glioma-targeted therapy [22]. 
We chose G5 PAMAM as the gene vector in the present study because its many surface 
amine groups enable efficient complex formation with ASODNs through charge-based 
interactions. Western blot analysis demonstrated the binding of G5 PAMAM to ASODNs, 
with an optimum ASODN/PAMAM ratio of 16:1. TEM analysis revealed that the complexes 
were >70 nm in size, and this small size likely enabled the efficient transfer of ASODNs to 
cells that we observed by flow cytometry. We used ASODNs directly labeled with 
fluorescent probes, such that flow cytometry directly reflected the uptake of the ASODN by 
the tumor. ASODN uptake mediated by PAMAM increased twofold in comparison with 
oligofectamine. The high uptake of ASODNs resulted in significant down-regulation of 
EGFR, suggesting that PAMAM mediated high efficiency transfection of C6 tumor cells with 
ASODNs. This high transfection efficiency can be attributed to not only the small size of the 
complexes, but also to the ‘proton sponge’ effect of PAMAM,31 in which the acidification of 
tertiary amino groups on PAMAM in the endosome increases the osmotic pressure within 
the endosome, leading to the release of ASODNs into cytoplasm.  
However, while nonderivatized PAMAM achieves high efficiency transfection, its low 
targeting efficiency needs to be improved. One strategy to achieve this is the 
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derivatization of PAMAM with ligands. Various ligands such as folic acid, transferring, 
and lactoferrin have been conjugated to PAMAM, thus enabling efficient gene targeting to 
tumors or brain. We chose folic acid as the functional ligand with which to modify 
PAMAM because of its low immunogenicity, unlimited availability, functional stability, 
defined conjugation chemistry, and a favorable nondestructive cellular internalization 
pathway.23 More importantly, the receptor for folic acid is a cell-proliferation protein that 
is overexpressed in many types of cancer cells.32–34 The expression levels of folate 
receptor in tumors have been reported to be 100–300 times higher than those observed in 
normal tissue.35 Although some ambiguity surrounds the expression level of the folate 
receptor in brain tumors,36 our results demonstrate that conjugation with folic acid 
enhanced the uptake of ASOND/PAMAM complexes by tumor cells and resulted in 
greater inhibition of EGFR expression in comparison with the native dendrimer. The in 
vivo study also demonstrates the superiority of FAPAMAM over either PAMAM or 
oligofectamine as a vector for mediating ASODN gene therapy. Dynamic contrast MRI 
scanning indicated significant suppression of tumor growth 2 weeks after C6 cell 
implantation (Fig. 2), which prolonged the survival time of rats in the FA-PAMAM-
mediated therapeutic groups. 
In the first place, we evaluated the efficiency of folate-PAMAM dendrimers conjugates (FA-
PAMAM) for the in situ delivery of therapeutic antisense oligonucleotides (ASODN) that 
could inhibit the growth of C6 glioma cells. Folic acid was coupled to the surface amino 
groups of G5-PAMAM dendrimer (G5D) through a 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide bond, and ASODNs corresponding to rat epidermal growth factor 
receptor (EGFR) were then complexed with FA-PAMAM. At an ASODN to PAMAM ratio of 
16:1, agarose electrophoresis indicated that antisense oligonucleotides were completely 
complexed with PAMAM or FA-PAMAM. The ASODN transfection rates mediated by FA-
PAMAM and PAMAM were superior to oligofectamine, resulting in greater suppression of 
EGFR expression and glioma cell growth. Stereotactic injection of EGFR ASODN:FA-
PAMAM complexes into established rat C6 intracranial gliomas resulted in greater 
suppression of tumor growth and longer survival time of tumor-bearing rats compared with 
PAMAM and oligofectamine-mediated EGFR-ASODN therapy. The current study 
demonstrates the suitability of folate-PAMAM dendrimer conjugates for efficient EGFR 
ASODN delivery into glioma cells, wherein they release the ASODN from the FA-PAMAM 
to knock down EGFR expression in C6 glioma cells, both in vitro and in vivo. FA-PAMAM 
may thus represent a novel delivery system for short oligonucleotides in glioma-targeted 
therapy. 
4.2 Co-delivery of as-mir-21 and 5-fu by poly(amidoamine) dendrimer attenuates 
human glioma cell growth in vitro 
The efficacy of conventional chemotherapy is limited owing to the low therapeutic index of 
many anticancer drugs, as well as intrinsic or acquired drug resistance. To circumvent these 
difficulties, novel therapeutic strategies have been developed, and one attractive strategy is 
the combination of gene therapy with chemotherapy. 
MicroRNAs have been demonstrated to be deregulated in different types of cancer. miR-21 
is a key player in the majority of cancers. Down-regulation of miR-21 in glioblastoma cells 
leads to repression of cell growth, increased cellular apoptosis and cell-cycle arrest, which 
can theoretically enhance the chemotherapeutic effect in cancer therapy.  
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Fig. 2. Contrast-enhanced coronal MR images of representative animals in the ASODN, 
Oligofectamine/ASODN, PAMAM/ASODN, FA-PAMAM/ASODN group at 1, 2, and 
3weeks after tumor xenograft. Four animals in PAMAM/ASODN and FA-
PAMAM/ASODN reached the 3-week time point, preventing a valid statistical comparison 
at that interval. The tumor in this animal is smaller in diameter and less contrast-enhanced 
than the one in the animal without gene therapy. 
With positively charged primary amino groups on the surface, the PAMAM dendrimer can 
feasibly interact with biomolecules to form complexes through charge-based interactions, 
and protect them from rapid degradation by cellular endo- and exonucleases. Thus, the 
PAMAM dendrimer may be suitable for gene transfer or oligonucleotide delivery. Besides, 
because PAMAM has well-defined internal cavities and an open architecture, guest 
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molecules can become directly encapsulated into the macromolecule interior through 
hydrophobic interactions. In this study, the poly(amidoamine) (PAMAM) dendrimer was 
employed as a carrier to co-deliver antisense-miR-21 oligonucleotide (as-miR-21) and 5-
fluorouracil (5-FU) to achieve delivery of as-miR-21 to human glioblastoma cells and 
enhance the cytotoxicity of 5-FU antisense therapy.  
Taking advantage of hydrogen-bond interaction, we encapsulated 5-FU in the PAMAM 
nanoparticles simply by a membrane dialysis method. the encapsulation efficiency and 
loading efficiency of the drug were determined by UV spectroscopy to be 66.21 and 
31.77%, respectively. Through their charge-based interactions, 5-FU-PAMAM could 
conjugate with as-miR-21. The co-delivery of as-miR-21 not only significantly improved 
the cytotoxicity and chemosensitivity of 5-FU and dramatically increased the apoptotic 
percentage of the U251 cells but also brought down the migration ability of the tumor 
cells. The inhibitory effect toward brain tumors was evaluated by MTT assay, and 
measurements of cell apoptosis and invasion using the human brain glioma cell line U251. 
PAMAM could be simultaneously loaded with 5-FU and as-miR-21, forming a complex 
smaller than 100 nm in diameter. Both the chemotherapeutant and as-miR-21 could be 
efficiently introduced into tumor cells. The co-delivery of as-miR-21 significantly 
improved the cytotoxicity of 5-FU and dramatically increased the apoptosis of U251 cells, 
while the migration ability of the tumor cells was decreased. These results suggest that 
our co-delivery system may have important clinical applications in the treatment of miR-
21-overexpressing glioblastoma. 
We report the anticancer potential of a combination of 5-FU treatment and antisense miR-21 
technology using PAMAM dendrimers. PAMAM dendrimers, an available co-carrier of 
chemotherapeutant and as-miR-21, could effectively deliver 5-FU and as-miR-21 
simultaneously, forming complexes smaller than 100 nm in diameter. The small size of the 
complexes facilitated their effective uptake by tumor cells, so the chemotherapeutant and as-
miR-21 could be synchronously introduced to glioma cell for combined actions. The co-
delivery of as-miR-21 significantly improved the cytotoxicity of 5-FU and dramatically 
increased the level of apoptosis of U251 cells; it also decreased the migration abilities of the 
tumor cells. Our results provide invaluable information regarding the future application of 
drug–polymer complexes combined with gene therapy for cancer treatments. Taken 
together, our findings suggest that the combination of 5-FU treatment and as-miR-21 might 
be a potential clinical strategy for cancer chemotherapy [23]. 
4.3 MicroRNA-21 inhibitor sensitizes human glioblastoma cells to taxol using  
PAMAM dendrimer 
Chemotherapeutic drugs are fundamental in cancer management and are responsible for 
most cases of adjuvant treatment in patients with GBMs after surgical procedures. Recently, 
much attention has been focused on the use taxol on glioma, both in experimental studies 
and in clinical trails [24]. However, the median overall survival did not increase in patients 
treated by concurrent chemoradiotherapy.  
The successful of anti-cancer treatment are often limited by the development of drug 
resistance. Consequently, further studies that could enhance the therapeutic effect of taxol 
should be encouraged.Recent work has highlighted the involvement of non-coding RNAs, 
microRNAs(miRNAs) in cancer development, and their possible involvement in the evolu-
tion of drug resistance has been proposed.  
www.intechopen.com
PAMAM Dendrimer as Potential Delivery System for  
Combined Chemotherapeutic and MicroRNA-21 Gene Therapy 
 
509 
 
Fig. 3. Characterization of 5-FU/PAMAM/As-miR-21 complex. TEM image of 5-FU–
PAMAM–as-miR-21 complex, N/P = 16. Magnification 58 000×, scale bar = 100 nm (A). 
Release profiles of 5-FU from PAMAMand PAMAM–as-miR-21 complexes compared with 
free 5-FU (B). Cell uptake detected by flow cyctometry and fluorescent microscopy image of 
U251 cells after transfection with different complexes (C).  
Substantial data indicate that the oncogene microRNA 21 (miR-21) is significantly elevated in 
glioblastoma multiforme (GBM) and regulates multiple genes associated with cancer cell 
proliferation, apoptosis, and invasiveness. Thus, miR-21 can theoretically become a target to 
enhance the chemotherapeutic effect in cancer therapy. So far, the effect of downregulating 
miR-21 to enhance the chemotherapeutic effect to taxol has not been studied in human GBM. 
In this study, we combine taxol chemotherapy and miR-21 inhibitor treatment via 
polyamidoamine (PAMAM) dendrimers vector to evaluate the effects of combination 
therapy on suppression of glioma cells. The result indicated that the miR-21 inhibitor can 
decrease the proliferation of both U251 and LN229 cells and increase the cells’ sensitivity to 
taxol treatment. The taxol concentration causing 50% growth inhibition (IC50) of U251 cells 
is 400 nmol/mL; whereas, in combination with the miR-21 inhibitor (20 μmol/L) the IC50 
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Fig. 4. Effect of the miR-21 inhibitor on the chemo-sensitivity of U251 and LN229 cells to 
taxol treatment. The growth of U251 and LN229 cells were inhibited by the miR-21 inhibitor, 
taxol only, and the indicated combinations. The cells were treated with the miR-21 inhibitor 
complexed to PAMAM for 6 h at 37°C. The medium was then replaced with media 
containing various concentrations of taxol. After 72 h of incubation, an MTT assay was 
performed. Absorbance at 570 nm was normalized to the control (untreated cells) to 
determine cell viability. Each value represents the mean ±SD from triplicate determinations. 
An aqueous solution of taxol (circles) and miR-21 inhibitor-loaded PAMAM (triangle) was 
incubated with human glioblastoma U251 and LN229 cells for six days. Druginduced 
decrease in cell numbers was measured using the MTT assay. The miR-21 inhibitor 
enhanced taxol induced apoptosis. Flow cytometry analyses of propidium iodide-stained 
cells were performed in triplicate (B). miR-21 inhibitor and taxol induce G1 and S phase 
arrest on cell cycle distribution. U251 and LN229 cells were treated with the miR-21 
inhibitor and taxol alone or in combination, and cell cycle distributions were detected by 
Flow cytometry 48 h later (C). Evaluation of the expression of PTEN, EGFR, STAT3, and p-
STAT3 in human glioblastoma LN229 and U251 cell lines. Western blot of protein extracts 
from cells treated with the miR-21 inhibitor or taxol, alone or combination (D). The 
expression of b-actin was examined to ensure uniform protein loading in all lanes. 
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was 60 nmol/mL. Taxol can also increase the efficacy of the miR-21 inhibitor. For example, 
combination treatment reduced cell viability to 20% compared with 86% viability for miR-21 
inhibitor gene therapy alone. In LN229 cells, combination treatment with 20 μmol/L of the 
miR-21 inhibitor reduced the IC50 of taxol from 820 to 160 nmol/L . It is worth noting that 
the miR-21 inhibitor additively interacted with taxol on U251cells and synergistically on 
LN229 cells. 
Taxol treatment also increased the percentage of apoptotic cancer cells in miR-21 inhibitor 
transfected cells compared with control cells. Furthermore, treatment of the miR-21 
inhibitor-transfected cells with the anti-cancer drugs taxol resulted in significantly reduced 
cell viability and invasiveness compared with control cells. These results indicated that the 
miR-21 plays an important role in the resistance of brain cancer cells to chemotherapeutic 
drugs. Therefore, miR-21 inhibitor gene therapy combined with taxol chemotherapy might 
represent a promising novel therapeutic approach for the treatment of glioblastoma. 
Thus, the miR-21 inhibitor might interrupt the activity of EGFR pathways, independently of 
PTEN status. Meanwhile, the expression of STAT3 and p-STAT3 decreased to relatively low 
levels after miR-21 inhibitor and taxol treatment. The data strongly suggested that a 
regulatory loop between miR-21 and STAT3 might provide an insight into the mechanism of 
modulating EGFR/STAT3 signaling [25]. 
5. Conclusion 
MiR-21 was one of the most frequently overexpressed miRNA in human glioblastoma 
(GBM) cell lines which can serve as a therapeutic target for glioblastoma. We validated that 
downregulation of miR-21 inhibited the growth of GBM cell lines and induced apoptosis. 
These effects were only partially dependent on PTEN, highlighting the existence of multiple, 
and possibly yet unknown, targets of miR-21. Inhibition of miR-21 also suppressed EGFR 
and Akt activity. These observations were confirmed in in vivo xenograft experiments that 
showed the potential clinical relevance of miR-21-targeting agents. Targeting miR-21 by 
antisense or small-molecule compounds may represent new targeted therapeutic strategies 
for human cancers, including gliomas. 
PAMAM dendrimer has been reported to be good gene delivery candidate. Although the 
biological effects obtained from in vitro analysis of PAMAM and FA-PAMAM are 
approximate, our in vivo study implies that FAPAMAM is functionally effective for gene 
delivery into three-dimensional tissues. This may be due to folate-mediated targeting of 
ASODNs to folate receptor-expressing cells in solid tumors. Stereotactic administration, 
which enables FA-PAMAM-ASODNs to be injected directly into a tumor, may also produce 
better results than intravenous injection. Site-specific delivery remains the best choice to 
overcome gene delivery side effects and to increase its efficacy. 
Next, we exhibit the anticancer potential of a combination of 5-FU treatment and antisense 
miR-21 technology using PAMAM dendrimers. PAMAM dendrimers, an available co-
carrier of chemotherapeutant and as-miR-21, could effectively deliver 5-FU and as-miR-21 
simultaneously, forming complexes smaller than 100 nm in diameter. The small size of the 
complexes facilitated their effective uptake by tumor cells, so the chemotherapeutant and as-
miR-21 could be synchronously introduced to glioma cell for combined actions. The co-
delivery of as-miR-21 significantly improved the cytotoxicity of 5-FU and dramatically 
increased the level of apoptosis of U251 cells; it also decreased the migration abilities of the 
tumor cells. Our results provide invaluable information regarding the future application of 
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drug–polymer complexes combined with gene therapy for cancer treatments. Taken 
together, our findings suggest that the combination of 5-FU treatment and as-miR-21 might 
be a potential clinical strategy for cancer chemotherapy. 
Furthermore, the miR-21 inhibitor could enhance the chemo-sensitivity of human 
glioblastoma cells to taxol via PAMAM dendrimer. A combination of miR-21 inhibitor and 
taxol could be an effective therapeutic strategy for controlling. The above data suggested 
that in both the PTEN mutant U251 cell line and the PTEN wild-type LN229 cells, miR-21 
blockage could increase the chemosensitivity to taxol. It is worth noting that the miR-21 
inhibitor additively interacted with taxol on U251cells and synergistically on LN229 cells. 
Thus, the miR-21 inhibitor might interrupt the activity of EGFR pathways, independently of 
PTEN status. The miR-21 inhibitor enhanced the chemo-sensitivity of human glioblastoma 
cells to taxol and combination of the miR-21 inhibitor and taxol could be an effective 
therapeutic strategy for suppressing the growth of GBM. 
the growth of GBM by inhibiting STAT3 expression and phosphorylation. 
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